Tafenoquine: First Global Approval-Reference-Cited by-同舟云学术

Tafenoquine: First Global Approval

Published:2018-09 Issue:14 Volume:78 Page:1517-1523
ISSN:0012-6667
Container-title:Drugs
language:en
Short-container-title:Drugs

Author:

Frampton James E.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical)

Link

http://link.springer.com/article/10.1007/s40265-018-0979-2/fulltext.html

Reference38 articles.

1. Crockett M, Kain KC. Tafenoquine: a promising new antimalarial agent. Expert Opin Investig Drugs. 2007;16(5):705–15.

2. Campo B, Vandal O, Wesche DL, et al. Killing the hypnozoite—drug discovery approaches to prevent relapse in Plasmodium vivax. Pathog Glob Health. 2015;109(3):107–22.

3. Ebstie YA, Abay SM, Tadesse WT, et al. Tafenoquine and its potential in the treatment and relapse prevention of Plasmodium vivax malaria: the evidence to date. Drug Des Dev Ther. 2016;10:2387–99.

4. Adis Insight. Drug profile: tafenoquine; 2018.

5. GlaxoSmithKline. KRINTAFEL (tafenoquine) tablets, for oral use: US prescribing information. 2018. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210795s000lbl.pdf . Accessed 9 Aug 2018.

Cited by 50 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evaluation of the inhibitory effects of sitamaquine on Babesia infections;Parasitology International;2024-12

2. Tafenoquine-Atovaquone Combination Achieves Radical Cure and Confers Sterile Immunity in Experimental Models of Human Babesiosis;The Journal of Infectious Diseases;2024-01-03

3. Where do we stand? Insight on patented products and those under clinical trials;Advances in Antiparasitic Therapies and Drug Delivery;2024

4. Repurposing of the antimalarial agent tafenoquine to combat MRSA;mSystems;2023-12-21

5. Forward or Backward: Lessons Learned from Small Molecule Drugs Approved by FDA from 2012 to 2022;Molecules;2023-12-05